Grants and Contributions:
Title:
Testing the effectiveness of DB-207 in the treatment of disease
Agreement Number:
930607
Agreement Value:
$30,000.00
Agreement Date:
Jun 17, 2019 - Mar 31, 2020
Description:
Derm-Biome has optimized Betulinic Acid derivatives that have shown promise in several areas affecting skin health. With this study they aim to show efficacy in these areas, namely aging, inflammatory skin disease, wound healing, and skin cancer, in order to develop cosmetics, drugs, and potentially probiotics.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6B 3G6
Reference Number:
172-2019-2020-Q2-930607
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
759709884
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 32 days. The total amended value is -44,500 dollars.
Amendment Date
Dec 6, 2019
Recipient's Legal Name:
Derm-biome Pharmaceuticals Inc.
Federal Riding Name:
Vancouver Centre
Federal Riding Number:
59034
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: